Developing a Tool for Endometrial Cancer Prevention

This study aims to create an educational tool to help women and their doctors make informed decisions about preventing endometrial cancer (cancer of the uterus lining). The tool will focus on using a levonorgestrel-releasing intrauterine system (LNG-IUS), a small device placed in the uterus that releases hormones. We want to understand what women need and value when considering prevention options. You may be able to join if you are an unaffected woman, at least 18 years old, premenopausal, and do not have a history of endometrial cancer. The study will measure your preferences and understanding through questionnaires over about one year. The goal is to develop a web-based tool in English and Spanish to help prepare you for discussions with your doctor.

Study design
This is an observational study aiming to enroll 270 women. It does not involve testing a new treatment but rather gathering information to create an educational tool.
What's involved
You will complete surveys using a questionnaire. This will occur over an average of one year.
Compensation
Not stated in the trial record.
Follow-up
Your preferences will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07382583

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~270 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Survey using a questionnaire

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient Utility Questionnaire
Measured over Through study completion; an average of 1 year
Levonorgestrel
Intrauterine Systems
Prevention
Endometrial Cancer
2 sites across 1 states
Texas2
  • Larissa A Meyer, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

N/A
  • Patient Utility QuestionnaireThrough study completion; an average of 1 year